Phase
Condition
Pain (Pediatric)
Cancer
Hypogonadism
Treatment
testosterone 1.62% gel
placebo gel
Clinical Study ID
Ages > 55 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Men with active solid or hematologic (blood) cancers who have received or arereceiving chemo- and/or radiation therapy. Patients who have no evidence of disease (NED) for 60 months or less, which means that they are <60 months from their lasttreatment (chemotherapy and/or radiation therapy) will be included.
Age: 55 years and older
Life expectancy of at least 6 months.
Serum testosterone, measured by mass spectrometry (gold standard method), of <348ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range fortotal testosterone in healthy men is 348 ng/dL and the lower limits of freetestosterone is <70 pg/ml in the Framingham Heart Study sample. As sex hormonebinding globulin levels may be elevated in some men with cancer (resulting inelevation in total testosterone level), some of these symptomatic men may still behypogonadal despite having total testosterone above this cut-off limit, but theirfree testosterone levels may still be below the lower limit of normal. Thus, menwith free testosterone <70 pg/mL will be included.
Fatigue. Fatigue was selected as it is a highly prevalent symptom in cancerpatients. Fatigue will be defined as a score on FACIT-Fatigue subscale of <40, whichbest divides cancer patients from the general population with accuracy.
Ability and willingness to provide informed consent
Exclusion
Exclusion Criteria:
Men with current or prior history of prostate, breast, testicular, or adrenalcancers.
Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months
Hematocrit >48%, serum creatinine >2.5 mg/dL
PSA >4 ng/ml; nodule or induration on digital rectal exam
Severe untreated sleep apnea
Uncontrolled congestive heart failure
Myocardial infarction, acute coronary syndrome, revascularization surgery, stroke orthromboembolism (of any etiology) within 6 months
Known history of thrombophilia due to a genetic mutation (e.g. Factor V Leiden)
Previous stroke with residual cognitive or functional deficits
Inability to provide informed consent; MMSE score <24
Poorly controlled diabetes as defined by hemoglobin A1c >10.0%
Body mass index (BMI) >40 kg/m2
Bipolar disorder or schizophrenia
Study Design
Study Description
Connect with a study center
Georgia Cancer Center at Augusta University
Augusta, Georgia 30912
United StatesActive - Recruiting
Brigham and Women's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
The Massey Cancer Center at Virginia Commonwealth University
Richmond, Virginia 23298
United StatesSite Not Available
Veterans Affairs Puget Sound Health Care System
Seattle, Washington 98108
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.